Tenofovir was approved by food and drug administration (FDA) for treatment of chronic B hepatitis in 2008. To evaluate the primary efficacy of Tenofovir, 305 patients treated by Topflovir (26 cases), Planovir (12 cases), Tenofovir Stada (138 cases) and Getino-B (129 cases) were enrolled in this study. HBV DNA, AST, ALT, total Bilirubin were measured at 0, 1, 3, 6, 12, 24, 30, 36 months of the course of therapy. Results showed that 155/305 (50.8 percent) patients were treated by one of following antiviral drugs: Lamivudine, Adefovir or Entecavir. Level of HBV DNA before of treatment was 4.5 x 10 exponent 8 + or - 2.3 x 10 exponent 3 copies/ml. After 1 month of therapy of Tenofovir, 305/305 (100 percent) patients have HBV DNA decreased at least 2log, with 280/305 (91.8 percent) patients decreased more than 3log; After 3 months of therapy 275/305 (90.16 percent) patients have HBV DNA 100 copies/ml; After 6 months of therapy 295/305 (96.7 percent) have HBV DNA 100 copies/mi. Mean of follow up was 18 months (6-36 months) without any antiviral resistance, side effect was observed. There is no significant difference between Topflovir, Planovir, Tenofovir Stada and Getino-B in treatment for chronic B hepatitis. Thus, Tenofovir is an efficacy medication for treatment of chronic B hepatitis.
- Đăng nhập để gửi ý kiến